Solventum (SOLV) Research | Aerarium Research

Forward Estimates

EPS Estimates

Current Qtr

$1.89

$1.78$1.95

vs $1.69+11.9%

11 analysts

Next Qtr

$1.43

$1.32$1.66

vs $1.50-4.6%

11 analysts

Current Yr

$6.55

$6.34$6.60

vs $6.11+7.3%

15 analysts

Next Yr

$7.04

$6.55$7.32

vs $6.55+7.4%

15 analysts

Revenue Estimates

Current Qtr

$2.15B

$2.10B$2.17B

vs $2.16B-0.3%

9 analysts

Next Qtr

$1.97B

$1.95B$1.98B

vs $2.10B-6.1%

9 analysts

Current Yr

$8.19B

$8.10B$8.24B

vs $8.32B-1.6%

12 analysts

Next Yr

$8.48B

$8.38B$8.54B

vs $8.19B+3.5%

12 analysts

SEC filings →

View all 10-K, 10-Q, and 8-K filings for SOLV on EDGAR.

SOLV filing events and research context
Filed	Item	Context
Feb 27, 2026	business	Solventum Corporation is a global healthcare company operating through three primary segments: MedSurg, Dental Solutions, and Health Information Systems. MedSurg, the largest segment (57.9% of 2025 sales), provides wound care, surgical supplies, and infection prevention technologies. Dental Solutions (16.2% of sales) offers orthodontic and restorative products, while Health Information Systems (16.3% of sales) delivers software for revenue cycle management, coding automation, and clinical documentation. The company competes in highly fragmented, innovation-driven markets against major players such as Becton Dickinson, Dentsply Sirona, Optum, and Microsoft (Nuance). Solventum’s competitive strategy relies on deep material and data science expertise, a global commercial footprint spanning 90 countries, and a robust R&D pipeline supported by approximately 2,000 employees. Key risks include intense global competition, evolving healthcare reimbursement policies that prioritize cost containment, and stringent environmental, health, and safety (EHS) regulations, including emerging restrictions on PFAS. The company manages a complex global supply chain, currently transitioning from 3M-supported infrastructure to independent capabilities. While Solventum utilizes a broad patent and intellectual property portfolio, it views its manufacturing know-how and customer relationships as its most critical competitive advantages.
Feb 27, 2026	mda	Solventum operates as a standalone global healthcare company following its spin-off from 3M, managing a portfolio across three primary segments: MedSurg, Dental Solutions, and Health Information Systems. The company’s 2025 financial performance was significantly impacted by the $4 billion divestiture of its Purification and Filtration business, which generated a $1.5 billion net gain. While total company net sales grew 0.9% to $8.3 billion, organic growth reached 3.3%, driven by strong performance in MedSurg and Health Information Systems. Management identifies key growth drivers in aging demographics, the shift toward lower-cost care sites, and the integration of AI and digital data-driven solutions to reduce administrative waste. However, profitability faces headwinds from the costs of establishing standalone operations, including higher compensation, equity-based awards, and supply chain separation expenses. Additionally, the company is navigating inflationary pressures, including logistics costs and new tariffs. Liquidity remains supported by cash from operations and access to credit facilities, though the company utilized proceeds from the Purification and Filtration divestiture to reduce debt, including the repayment of $2.0 billion in senior notes. Future performance remains sensitive to the successful transition of manufacturing and supply chains away from 3M and the ongoing management of debt obligations.
Feb 27, 2026	risk_factors	Solventum (SOLV) faces significant operational and financial risks following its 2024 spin-off from 3M. A primary concern is the company’s reliance on master supply and transition manufacturing agreements with 3M, which have contributed to increased product costs due to supply chain mark-ups, logistics expenses, and new tariffs. The company is actively working to relocate manufacturing and supply sources to achieve independence, a process that requires substantial capital expenditure and ongoing operational adjustments. Financial performance is sensitive to macroeconomic factors, including foreign currency volatility and interest rate fluctuations, which the company manages through its own hedging programs. Solventum also carries a significant debt load, and while it recently used proceeds from the $4 billion divestiture of its Purification and Filtration business to pay down debt, it remains subject to restrictive covenants and the costs of servicing its remaining obligations. Legal and regulatory risks are prominent, particularly regarding product liability litigation related to the Bair Hugger patient warming system, for which Solventum has assumed indemnification obligations from 3M. Furthermore, the company’s growth strategy depends on its ability to successfully integrate acquisitions like Acera Surgical, optimize its cost structure through the "Transform for the Future" initiative, and navigate evolving healthcare reimbursement models and administrative cost pressures.

Filed

Item

Context

Feb 27, 2026

business

Solventum Corporation is a global healthcare company operating through three primary segments: MedSurg, Dental Solutions, and Health Information Systems. MedSurg, the largest segment (57.9% of 2025 sales), provides wound care, surgical supplies, and infection prevention technologies. Dental Solutions (16.2% of sales) offers orthodontic and restorative products, while Health Information Systems (16.3% of sales) delivers software for revenue cycle management, coding automation, and clinical documentation. The company competes in highly fragmented, innovation-driven markets against major players such as Becton Dickinson, Dentsply Sirona, Optum, and Microsoft (Nuance). Solventum’s competitive strategy relies on deep material and data science expertise, a global commercial footprint spanning 90 countries, and a robust R&D pipeline supported by approximately 2,000 employees. Key risks include intense global competition, evolving healthcare reimbursement policies that prioritize cost containment, and stringent environmental, health, and safety (EHS) regulations, including emerging restrictions on PFAS. The company manages a complex global supply chain, currently transitioning from 3M-supported infrastructure to independent capabilities. While Solventum utilizes a broad patent and intellectual property portfolio, it views its manufacturing know-how and customer relationships as its most critical competitive advantages.

Feb 27, 2026

mda

Solventum operates as a standalone global healthcare company following its spin-off from 3M, managing a portfolio across three primary segments: MedSurg, Dental Solutions, and Health Information Systems. The company’s 2025 financial performance was significantly impacted by the $4 billion divestiture of its Purification and Filtration business, which generated a $1.5 billion net gain. While total company net sales grew 0.9% to $8.3 billion, organic growth reached 3.3%, driven by strong performance in MedSurg and Health Information Systems. Management identifies key growth drivers in aging demographics, the shift toward lower-cost care sites, and the integration of AI and digital data-driven solutions to reduce administrative waste. However, profitability faces headwinds from the costs of establishing standalone operations, including higher compensation, equity-based awards, and supply chain separation expenses. Additionally, the company is navigating inflationary pressures, including logistics costs and new tariffs. Liquidity remains supported by cash from operations and access to credit facilities, though the company utilized proceeds from the Purification and Filtration divestiture to reduce debt, including the repayment of $2.0 billion in senior notes. Future performance remains sensitive to the successful transition of manufacturing and supply chains away from 3M and the ongoing management of debt obligations.

Feb 27, 2026

risk_factors

Solventum (SOLV) faces significant operational and financial risks following its 2024 spin-off from 3M. A primary concern is the company’s reliance on master supply and transition manufacturing agreements with 3M, which have contributed to increased product costs due to supply chain mark-ups, logistics expenses, and new tariffs. The company is actively working to relocate manufacturing and supply sources to achieve independence, a process that requires substantial capital expenditure and ongoing operational adjustments. Financial performance is sensitive to macroeconomic factors, including foreign currency volatility and interest rate fluctuations, which the company manages through its own hedging programs. Solventum also carries a significant debt load, and while it recently used proceeds from the $4 billion divestiture of its Purification and Filtration business to pay down debt, it remains subject to restrictive covenants and the costs of servicing its remaining obligations. Legal and regulatory risks are prominent, particularly regarding product liability litigation related to the Bair Hugger patient warming system, for which Solventum has assumed indemnification obligations from 3M. Furthermore, the company’s growth strategy depends on its ability to successfully integrate acquisitions like Acera Surgical, optimize its cost structure through the "Transform for the Future" initiative, and navigate evolving healthcare reimbursement models and administrative cost pressures.

Forward Estimates

SOLV filing events and research context

Keep researching SOLV

Related tickers

Related explainers

Forward Estimates